1. Introduction
Venous thromboembolism (VTE) is a major concern for cancer patients. In patients with cancer, the overall risk of VTE is nine times higher than it is in the general population [ 1 ]. This correlation can be explained mostly by elevation of prothrombotic factor expression by either cancer cells or cells forming the tumor microenvironment [ 2 , 3 ]. These mechanisms are self-reinforcing processes because platelets present the ability to promote progression of the cancer [ 4 , 5 ]. Among molecular mechanisms of tumor cell-induced platelet aggregation (TCIPA), scientists described production of tissue factor (TF) by cancer cells [ 6 ], production and regulation of thrombopoietin (TPO) [ 7 ], and granulocyte colony stimulating factor [ 8 ]. Other mechanisms include adhesive protein production by cancer cells that allows for interaction with platelets; for example, P-selectin [ 9 ]. Variety of pro-thrombotic processes induced by the neoplastic process, combined with the perception of cancer as a chronic disease, elucidate the need for effective ways of VTE treatment and prophylaxis. Anticoagulant treatment is used to either prevent or treat thrombotic events. Therapeutic agents can be divided into two groups: parenteral and oral. The parenteral group includes unfractionated heparins (UFHs), low-molecular-weight heparins (LMWHs), fondaparinux, and bivalirudin, whereas oral agents are vitamin K antagonists (VKAs) and non-vitamin K antagonist direct oral anticoagulants (DOACs). UFHs have been mostly replaced with LMWHs, whereas VKAs are being replaced with DOACs. There is a growing body of evidence for DOAC use in cancer patients, e.g., in thromboprophylaxis and myeloproliferative neoplasms [ 10 , 11 , 12 , 13 , 14 ]. In a systematic review performed to assess the patients’ values and preferences regarding VTE, it was reported that disease-related health presents a broad spectrum of impact on patients’ lives. In the same report, it was highlighted that the need for therapy monitoring or dietary changes were not preferred [ 15 ]. Patients are concerned with the presence of cancer more than with VTE occurrence [ 16 , 17 ]. Receiving treatment with a lower possible interference with cancer treatment was highlighted [ 17 ]. Overall, oral medication is more desired over subcutaneous [ 15 , 16 , 18 , 19 , 20 ]. From patients’ perspective, the availability of a DOAC activity reversal agent was not a priority [ 20 , 21 ]. It is important to include the patient in the therapy decision-making process [ 15 , 16 ]. The aim of this review is to analyze the available literature on DOACs and their use in cancer patients. The article search was conducted in February 2023 within the PubMed and Scopus databases. To be included, the article (or at least the abstract) had to have been published in English, published after 2010, and carried out on humans. Case reports were excluded. The following combination of search terms was applied to find articles: ((cancer) OR (neoplasm)) and ((thrombosis) OR (VTE)) and ((NOAC*) OR (DOAC*) OR (LMWH*) OR (VKA) OR (VKAs)). A total of 446 articles in PubMed and 295 in SCOPUS were identified; after exclusion of duplicates and examining the abstract and/or full text, 83 articles remained ( Figure 1 ).
2. DOACs: Revolution in Anticoagulant Treatment
NOACs (novel oral anticoagulants) are a group of anticoagulants that were introduced in October 2010 [ 22 ]. As time passed, the term “novel” became inappropriate, so to keep the acronym unchanged, its current meaning is non-vitamin K antagonist oral anticoagulants. This term was met with opposition from some members of the scientific community due to its lexical inaccuracy, leading to the creation of a new term: DOACs (direct-acting oral anticoagulants), proposed by the International Society on Thrombosis and Haemostasis in 2015. Other alternatives to the term present in the current scientific literature are target-specific oral anticoagulants (TSOACs), oral direct inhibitors (ODIs), and specific oral direct anticoagulants (SODAs) [ 23 ]. DOACs are the first line of anticoagulant treatment for many diseases. The importance of this group was confirmed by the WHO, which added DOACs to the World Health Organization’s Model List of Essential Medicines in 2019 [ 24 ]. Four main drugs belong to the group of DOACs: rivaroxaban, dabigatran, edoxaban, and apixaban. Their main mechanism of action is presented in Figure 2 .
Rivaroxaban is a direct inhibitor of factor Xa, binding directly to the active site of this factor [ 25 ]. It also has the ability to inhibit the activity of prothrombinase [ 26 ]. Rivaroxaban is a drug that is quickly absorbed after oral administration, with peak concentrations appearing after 2–4 h [ 27 ]. Current recommendations to use rivaroxaban include: prevention of atherothrombotic events in adult patients after an acute coronary syndrome with elevated cardiac biomarkers; prevention of atherothrombotic events in adult patients with coronary artery disease or symptomatic peripheral artery disease at a high risk of ischaemic events; prevention of VTE in adult patients undergoing elective hip or knee replacement surgery; treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); prevention of recurrent DVT and PE in adults; prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) with one or more risk factors; and treatment of VTE and prevention of VTE recurrence in children and adolescents under 18 years of age [ 28 , 29 , 30 ].
Apixaban is a drug approved by the US Food and Drug Administration (FDA) in 2012. It is a highly selective inhibitor of factor Xa. It does not affect platelet aggregation. Its total bioavailability stands at about 50%, with peak plasma concentrations after 3–4 h [ 31 ]. Therapeutic indications of apixaban include: prevention of VTE events in adult patients who have undergone elective hip or knee replacement surgery; prevention of stroke and systemic embolism in adult patients with NVAF who have one or more risk factors; treatment of DVT and PE; and prevention of recurrent DVT and PE in adults [ 32 , 33 , 34 ].
Edoxaban is a direct and specific inhibitor of factor Xa, with selectivity towards factor Xa nearly 10,000 times higher than thrombin [ 26 ]. Edoxaban was registered by the FDA in 2015. The highest concentration in plasma is noted after 1–2 h, with the half-life of the molecule being 10–12 h [ 35 ]. Currently, edoxaban is registered for the following therapeutic indications: prevention of stroke and systemic embolism in adult patients with NVAF with one or more risk factors; treatment of DVT and pulmonary embolism (PE); and prevention of recurrent DVT and PE in adults [ 36 , 37 , 38 ].
Dabigatran etexilate is a factor IIa inhibitor. It is produced in the form of a prodrug that must be transformed into its active form by microsomal carboxylesterases in the liver. Due to its poor availability (around 6%), there is a need for the administration of high dabigatran dosages [ 39 ]. The half-life of dabigatran particles is 12–17 h, with the highest serum concentration achievable between 1 and 2 h after admission. It is important to mention that dabigatran is mainly eliminated by the kidneys; therefore, it is contraindicated in patients with renal failure [ 40 ]. Therapeutic indications of dabigatran include primary prevention of VTE events in adult patients who have undergone elective total hip or total knee replacement surgery; prevention of stroke and systemic embolism in adult patients with NVAF who have one or more risk factors; treatment of DVT and PE; and prevention of recurrent DVT and PE in adults [ 41 , 42 , 43 ].
3. DOACs’ Potential to Replace Classical VKAs in the Therapy of Patients with Cancer
VKAs were the first group of oral anticoagulant drugs used in therapy. They have been available since the 1950s. VKAs display their anticoagulant abilities by inhibiting vitamin K reductase, leading to the depletion of coagulation proteins (factors II, VII, IX, and X), which depend on vitamin K in their synthesis pathways [ 44 ]. Compared to DOACs, VKAs have various limitations, including slow onset and late offset of therapeutic activity. The dose of VKAs is not fixed, as in the case of DOACs, because it has to take into consideration the genetic polymorphism of patients, their metabolism, and their daily intake of vitamin K. This leads to the need for frequent monitoring of anticoagulation treatment, which is inconvenient for patients and costly for the health care system. In addition, the risk of bleeding is lower in DOACs compared to VKAs [ 12 ]. Studies have shown that DOACs constitute a group of drugs that overtake traditional VKAs in anticoagulation treatment [ 45 , 46 , 47 ]. Papers provide evidence of DOACs’ benefits compared to traditional therapy with VKAs [ 48 , 49 , 50 , 51 , 52 , 53 , 54 ]. In cancer patients, VKA use was associated with a higher risk of cancer-associated thrombosis (CAT) and recurrence of bleeding compared with the general population [ 55 , 56 ]. There is also a higher risk of VTE recurrence and anticoagulant-associated bleeding [ 53 , 57 , 58 ]. Administration of VKAs is also strained because of multiple drug–drug interactions in cancer patients. The major advantages of DOACs for patients with cancer in comparison to VKAs are predictable pharmacokinetics and pharmacodynamics, few drug–drug and drug–food interactions, and a wide therapeutic window [ 59 ]. Additionally, the persistence in DOACs’ usage is higher than that of VKAs [ 60 ]. Studies provide evidence that the administration of DOACs is associated with a lower risk of major bleeding (MB) in cancer patients with VTE. In contrast to DOACs, VKAs are also not recommended for acute VTE in patients with cancer [ 61 , 62 , 63 , 64 , 65 , 66 ]. Patients with active cancer treated with VKAs have a higher risk of death than patients treated with DOACs [ 67 ]. In patients with cancer and atrial fibrillation (AF), DOACs prove to be safer than traditional VKAs, leading to fewer incidences of MB, combined ischemic stroke/systemic embolism, intracranial bleeding, and major gastrointestinal bleeding [ 68 ]. In patients with AF and a history of cancer, DOACs seem to be safer than VKAs in patients aged < 75 years [ 69 , 70 , 71 ]. In partial contradiction to the data discussed in the previous statement, one of the studies analyzed states that in patients with gastrointestinal (GI) tract malignancies with and without comorbid AF, oral anticoagulant-related GI bleeding was more likely to appear in patients treated with DOACs in comparison to VKAs, especially in groups of older men [ 72 , 73 ]. The risk of bleeding is also reported to be higher in older men with genitourinary tract malignancies [ 73 ]. DOACs are postulated to decrease the risk of primarily DVT events in patients exposed to high-risk chemotherapy, with VKAs lacking this activity in a head-to-head comparison [ 74 ]. Patients with cancer using DOACs have a lower risk of ischemic stroke, systemic embolism, and myocardial infarction [ 75 , 76 , 77 ] compared to VKA users. A study concerning the anticoagulant treatment of post-stroke patients with cancer shows another example of DOACs’ higher value than traditional VKA treatment [ 78 ].
4. Could DOACs Be Used as a Substitute for Classic Anticoagulant LMWH Therapy?
Low-molecular-weight heparins (LMWHs) are considered a recommended treatment for VTE in cancer patients. They were introduced as an alternative to VKAs. LMHWs inhibit coagulation through the activation of antithrombin III, which binds to factor Xa and causes its inhibition. This results in the final common path not being activated. Xa inactivation means that prothrombin is not activated to thrombin, thereby not converting fibrinogen into fibrin for the formation of a clot [ 79 , 80 ]. The advantages of DOAC therapy are oral administration [ 62 , 75 , 81 ], rapid onset and offset of action [ 74 , 82 , 83 , 84 , 85 ], no need for therapy monitoring [ 81 , 82 , 83 , 86 , 87 , 88 ], patient comfort [ 61 , 83 ], lower therapy cost than LMWHs, fixed doses [ 83 , 84 ], few drug–drug or food–drug interactions, predictable anticoagulation effects, and the presence of specific reversal agents [ 81 , 82 , 88 ]. The disadvantages of DOACs are lower efficacy than LMWHs in vomiting patients, less clinical experience than LMWHs, and caution advised in renal insufficiency [ 82 , 89 , 90 ]. Additionally, there is a lack of studies in obese patients and those with platelet counts lower than 50,000 mg/L [ 90 ]. There is a concern in terms of monitoring DOACs’ anticoagulation effect, but UPLC–MS/MS is being proposed as a potential solution [ 91 ]. DOACs had a higher, yet nonsignificant, risk of MB compared with LMWHs [ 55 ]. However, it was reported that GI bleeding associated with the use of DOACs may be a cancer revelator [ 70 ]. It is important to assess patients’ risk of VTE occurrence, which can be done using the Khorana Risk Score (KRS). KRS is a point-based score used to assess the risk of VTE occurrence in ambulatory cancer patients. It divides the population into three risk categories: low, intermediate and high. It takes into account five parameters, which are: the type of cancer, with distinctions of high risk (pancreas and stomach) and low risk (lung, lymphoma, gynecologic, bladder, testicular); a prechemotherapy platelet count of 350 × 10 9 /L or more; a hemoglobin level of less than 100 g/L or the use of red-cell growth factors; a prechemotherapy leukocyte count of more than 11 × 10 9 /L; and a BMI of 35 kg/m 2 or more [ 92 , 93 ]. A review performed by Lenihan DJ et al. provides evidence that DOACs are not inferior to LMWHs in terms of treatment of VTE. It was also noted that not every cancer patient should receive routine pharmacologic thromboprophylaxis, but those who are included in the high-risk group should be treated with either DOACs or LMWHs [ 92 , 93 , 94 , 95 , 96 , 97 ]. In a Cochrane meta-analysis, it was found that there were no differences between DOACs and conventional anticoagulation of recurrent VTE. However, the evidence was moderate or low [ 98 ]. When discontinuing the anticoagulant therapy, patients with a metastatic disease are at greater risk of VTE recurrence at 6 and 12 months; however, with regard to incidental VTE, the risk is lower in this time period [ 99 ]. RIETE registry’s data analysis displayed a more consistent risk of subsequent VTE events in cancer patients with superficial vein thrombosis (SVT) than in cancer patients with DVT during the first 3 months of anticoagulant therapy [ 100 ]. Studies on patients with hematological malignancies showed a lower bleeding or recurrence rate in the DOAC group compared to the LMWH group [ 101 ]. With regard to incidental PE, its single subsegmental type was not significantly associated with the risk of recurrent VTE, whereas the multiple type presented an increased risk of recurrent VTE [ 102 ]. A high risk of recurrence in patients with gynecological and pancreatic or hepatobiliary cancer was also reported. In the same report, there is a mention of ECOG status of 1 or greater being a risk for recurrence [ 103 ]. In another systematic review, DOACs were displayed as more effective than LMWHs in the prevention of recurrent VTE (rVTE), yet they were associated with an increased risk of MB and clinically relevant non-major bleeding (CRNMB) [ 104 ]. Rivaroxaban and LMWHs reduced the occurrence of peripherally inserted central venous catheter-related upper extremity VTE in cancer patients during chemotherapy [ 105 ]. In a randomized control trial (RCT) comparing rivaroxaban and enoxaparin in patients undergoing gynecological cancer surgery, it was proven that those agents had similar rates of thrombotic and bleeding events [ 106 ]. In a study conducted on the Asian population, similar rates of rVTE were reported when DOACs and enoxaparin treatment were compared. DOACs had similar VTE recurrence risk and MB at 12 months follow-up. The results of this study also suggest that there might be an association between race or ethnic differences and GI bleeding in treatments with DOACs in cancer-associated VTE (CAVTE) [ 107 ]. VTE recurrence was lower in patients treated with rivaroxaban than LMWHs [ 55 , 108 ]. In a systematic review on rivaroxaban and LMWHs, it was discovered that, compared to LMWHs, rivaroxaban has a lower risk of VTE recurrence, lower all-cause mortality, and a better overall NCB [ 56 ]. In a meta-analysis performed by Camilli M et al., the significant superiority of DOACs over LMWHs was reported in treating rVTE in cancer patients [ 109 ]. The major concern of DOACs therapy is their bleeding risk. In a phase III trial, edoxaban was reported to be noninferior to dalteparin in patients with CAVTE, with regard to the combined outcome of rVTE or MB [ 110 ]. DOACs treatment was associated with a lower risk of GI bleeding than enoxaparin. With regard to MB, there were no increased events. They were shown to have a lower rate of major GI bleeding when compared with enoxaparin [ 107 ]. DOACs are also preferred when anticoagulation therapy is going to be extended. In patients with CAT treated with DOACs, caution is required when patients are at higher risk of bleeding or drug-to-drug interactions [ 111 ]. Interestingly, in an observational study, the median time to a minor or MB occurrence was shorter in DOACs than LMWHs [ 85 ]. Xa inhibitors were associated with an increased overall risk of bleeding events when compared with LMWHs, with the majority of these events being CRNMB. The GI tract was reported to be the most common bleeding site. Additionally, the risk of intracranial bleeding while treating CAVTE was presented as a significant concern [ 112 ]. Contrary to Hussain MR et al.’s findings, the risk of MB was reported not to increase during DOAC treatment; however, CRNMB and GI bleeding risk were reported to be increased, which is consistent with Hussain MR et al.’s meta-analysis. What is more, there is a report that says there is no evidence of a significant difference between rivaroxaban and LMWHs in terms of MB. However, in the same study, taking CRNMB into account, there was a higher prevalence in the rivaroxaban group [ 56 ]. Data gathered in the meta-analysis of Mohamed MFH et al. showed the potential superiority of rivaroxaban concerning a lower mortality rate when compared with LMWHs; however, the result displayed marked heterogeneity [ 56 ]. Additionally, DOACs may be associated with a lower risk of intracranial hemorrhage than LMWHs with regard to metastatic brain disease and venous thrombosis [ 86 ]. When considering the safety of DOAC therapy, it was shown in a pilot study that extended treatment with DOACs seems to be associated with similar effectiveness and safety as LMWHs [ 85 ], as well as in a recent meta-analysis that supports the safety and efficacy of DOACs as a CAT treatment [ 113 ]. Furthermore, this therapy is comparable with LMWHs in active cancer patients undergoing treatment for cryptogenic ischemic stroke; however, the study was conducted on a small sample size [ 114 ]. In terms of GI tumors, DOACs show a comparable safety profile with LMWHs [ 109 ]. If anticoagulation treatment is required beyond 6 months, DOACs and LMWHs are safe to use; however, DOACs are associated with a higher risk of bleeding [ 115 ]. In another review, Xa inhibitors were shown to be comparable to LMWHs with regard to the risk of recurrent PEs. No significant difference was reported between Xa inhibitors and LMWHs in the risk of a fatal VTE; however, this was based on very low certainty evidence [ 112 ]. For patients who suffer from multiple myeloma and receive thalidomide- or lenalidomide-based regimens combined with chemotherapy and/or dexamethasone, as well as individuals with locally advanced or metastatic pancreatic cancer, the recommended anticoagulants are apixaban and rivaroxaban or LMWHs. Interestingly, VKAs are no longer recommended. In terms of secondary prevention of VTE, recent RCTs and meta-analyses indicated that apixaban, one of the DOACs, had the best safety and efficacy profiles in this category. DOACs are suggested over LMWHs or VKAs when dealing with patients undergoing chemotherapy for newly diagnosed NVAF, with the exception of patients with luminal gastrointestinal cancers with an intact primary or patients with active gastrointestinal mucosal abnormalities such as duodenal ulcers, gastritis, esophagitis, or colitis [ 116 ]. In another review, DOACs are shown to be a preferred agent in AF unless there are strong contraindications [ 117 ]. It is important that cytochrome P450 3A4-related drug-to-drug interaction of DOACs can interfere with their pharmacokinetics [ 61 , 90 ]. Some reports provide lists of chemotherapeutic agents and immunosuppressants that can potentially interfere with DOACs’ basin of known metabolic pathway activity [ 48 , 87 ]. Most of the time, drug–drug interactions occur between tyrosine kinase inhibitors [ 48 , 87 , 118 ]. Other groups are small-molecule inhibitors [ 119 ], monoclonal antibodies i.e., alemtuzumab, hormonal agents, i.e., enzalutamide, and immune-modulating agents, i.e., cyclosporine [ 118 ]. It is important to highlight that DOACs will interfere differently with antineoplastic agents, with apixaban having the lowest potential to interact with antineoplastic agents [ 120 ]. There is still a lot of research to be done to investigate possible drug-drug interactions. Specific cancer cells may inhibit the thrombin generation provided by apixaban or enoxaparin. The combined presence of BXCP3 or MCF7 cells and platelets was linked to a weaker impact on the antithrombotic effect of apixaban than enoxaparin. Interestingly, the presence of BXCP3 or MCF7 cells separately impacted the inhibitory strength of apixaban and enoxaparin on a similar level [ 121 ]. Although DOACs are promising therapeutic agents, it is not uncommon for LMWHs to be recommended over DOACs, e.g., for patients who present a high risk of bleeding, such as GI cancer patients, those who require frequent dose adjustments with chemotherapy-induced thrombocytopenia, those who receive ongoing anticancer therapies with potential drug–drug interactions, as well as those with brain metastases [ 113 ]. In Table 1 , various treatment agents used in guidelines for treating thrombotic events in cancer patients are gathered.
Currently available guidelines are considering the role of DOACs in VTE prophylaxis among patients with cancers in three main settings. The first one being patients undergoing surgical treatment of malignancies with no distinction between classic and laparoscopic procedures. In this case, usage of DOACs is mostly not recommended [ 94 , 95 , 97 ], with the exception of apixaban, which is one of the recommended drugs in postoperative VTE prophylaxis [ 90 , 96 ]. In the case of hospitalized patients, DOACs are also not the recommended method of VTE prophylaxis [ 95 , 96 , 97 ]. Nevertheless, ASH Guidelines allow patients to continue using DOACs regimen when the prophylaxis was started before hospitalization [ 90 ]. The last group of patients widely discussed in the context of VTE prophylaxis are outpatients undergoing systemic chemotherapy or bone marrow transplantation. According to experts, VTE prophylaxis should be considered only in patients with high [ 90 , 94 , 95 , 96 ] or intermediate [ 97 ] risk of VTE (Khorana Risk Score two or higher). In this indication, DOACs are the recommended group of drugs alongside LMWH. It is important to mention that in patients with CVC, parenteral prophylaxis should be administered [ 94 ]. Recommendations discussed in the guidelines are reflected in conducted clinical trials. AVERT trail proved that thromboprophylaxis with apixaban reduced the risk of major VTE in most patients who were undergoing chemotherapy, same finding was made in subgroups of patients with gastrointestinal cancers, CVC presence, impaired renal function, and metastatic disease [ 124 , 125 , 126 , 127 , 128 ]. In the subgroup of patients initiating chemotherapy for recurrent disease, apixaban thromboprophylaxis was shown to be effective [ 129 ]. CASSINI study subgroups were analysed in field of thromboprophylaxis with rivaroxaban, and it was proved to be a viable therapeutic option [ 130 , 131 ]. In the pancreatic cancer subgroup, rivaroxaban was found to be potentially beneficial in VTE reduction [ 132 ]. However, in a placebo-controlled trial, no benefit of rivaroxaban treatment in high-risk ambulatory patients was displayed [ 133 ].
5. Clinical Trials
Presently, there are some clinical trials that are investigating DOACs in different setups. There is an ongoing study investigating whether drugs, inducing the CYP 3A4 isoenzyme of CYP450 and the P-gp transporter, significantly affect plasma levels of DOACs in patients with NVAF and VTE [ 134 ]. In this study, MACACOD DOACs are being investigated in terms of AF and rVTE [ 135 ]. In the CANVAS study, LMWHs and warfarin are compared to DOACs in cancer patients [ 136 ]. VICTORIE is a retrospective analysis of observational cohorts with VTE and active cancer or patients with VTE and a history of cancer who initiate anticoagulant treatment with a VKA, LMWHs, or DOACs [ 137 ]. Rivaroxaban’s anti-proliferative and other anti-cancer progression mechanisms are being assessed [ 138 ]. In OSCAR-SE, rivaroxaban is being compared with LMWHs [ 139 ]. A phase III RCT comparing rivaroxaban and placebo is being carried out [ 140 ]. Post-discharge prophylaxis with rivaroxaban in lung cancer patients is being investigated [ 141 ]. In VTE-POG, which is an ongoing open-label study of apixaban for VTE prevention in patients with newly diagnosed grade 4 glioma [ 142 ], there is a retrospective database analysis of health care claims data that investigates treating patients diagnosed with cancer and VTE with apixaban or LMWHs [ 143 ]. The ASTER study compares the effect of abelacimab relative to apixaban on VTE recurrence and bleeding in patients with CAVTE [ 144 ]. CASTA-DIVA investigated rivaroxaban compared with dalteparin in patients with CAT. Unfortunately, pre-defined criteria for noninferiority were not met because of an insufficient number of patients; however, its efficacy and safety results were consistent with those previously reported with DOACs [ 145 ]. The Caravaggio study reported noninferiority of oral apixaban to subcutaneous dalteparin treatment in CAT patients [ 146 ]. There is a report which sums up the role of DOACs in patients with CAT [ 147 ]. We did not identify ongoing studies that would include dabigatran or edoxaban as a single agent used in cancer patients.
6. Conclusions
Thrombotic events are a major concern in cancer patients, despite the constant efforts of physicians and scientists. The appearance of DOACs brought a new therapeutic option to the management of VTE. In this article, we showed that, in most cases, VKAs are being replaced with DOACs, whereas in terms of LMWHs, they are considered a substitute or alternative option. There are some major advantages to DOACs over VKAs, mainly fixed dosage and no need for therapy monitoring. The wide range of papers discussed in this review seem to support this statement in the therapy of patients with cancer. Nevertheless, there are still instances of VKAs superiority in comparison to DOACs that should not be omitted. Patients with GI and genitourinary tract malignancies, with particular emphasis on elderly men, are especially benefiting from VKAs therapy. A comparison between DOACs and LMWHs showed that their efficacy is predominantly comparable, although DOACs are more patient friendly in terms of their quality of life. It is also important to mention that there are still many uncertainties when it comes to DOACs usage in cancer patients with VTE. The main concerns revolve around the probable risk of MB and an insufficient amount of data and experience when it comes to treatment in obsessed patients and those with low plates count and renal insufficiency. Lack of strong evidence may lead to lower uptake of recent guidelines regarding prophylaxis with DOACs. Unfortunately, not every agent among the DOACs is equally researched. Rivaroxaban and apixaban are the main subjects of interest, with edoxaban and dabigatran being less popular in clinical trials. However, edoxaban was reported to be noninferior to subcutaneous dalteparin in the HOKUSAI-VTE study. The main concern when using DOACs is the higher risk of bleeding; however, there are some discrepancies between studies in this area. There is a possibility that ethnicity or race will be a field of particular interest for research, as it may affect the risk of bleeding. The presence of specific cancer cells may impact the efficacy of DOACs. Guidelines were found to vary in terms of therapeutic agents used in the management of thrombotic events. We identified some clinical trials that can contribute to standardizing the clinical approach for cancer patients. There is a need for further research on DOACs’ use in more specific situations. This review supports the use of DOACs in various clinical situations.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Author Contributions
Conceptualization, T.G. and K.B.; methodology, T.G., K.B. and M.C.; software, T.G.; validation, M.C. and D.Z.; formal analysis, M.C.; investigation, T.G. and K.B.; resources, T.G. and K.B.; data curation, M.C.; writing—original draft preparation, T.G., K.B. and M.C.; writing—review and editing, D.Z. and M.C.; visualization, T.G. and K.B.; supervision, M.C. and D.Z.; project administration, T.G.; funding acquisition, M.C. All authors have read and agreed to the published version of the manuscript.
Data Availability Statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Conflicts of Interest
The authors declare no conflict of interest.
References
1. Mulder F.I. Horvàth-Puhó E. van Es N. Van Laarhoven H.W.M. Pedersen L. Moik F. Ay C. Büller H.R. Sørensen H.T. Venous thromboembolism in cancer patients: A population-based cohort study Blood 2021 137 1959 1969 10.1182/blood.2020007338 33171494
2. Pastori D. Cormaci V.M. Marucci S. Franchino G. Del Sole F. Capozza A. Fallarino A. Corso C. Valeriani E. Menichelli D. A Comprehensive Review of Risk Factors for Venous Thromboembolism: From Epidemiology to Pathophysiology Int. J. Mol. Sci. 2023 24 3169 10.3390/ijms24043169 36834580 PMC9964264
3. Santoro C. Capone V. Canonico M.E. Gargiulo G. Esposito R. Sanna G.D. Parodi G. Esposito G. Single, dual, and triple antithrombotic therapy in cancer patients with coronary artery disease: Searching for evidence and personalized approaches Seminars in Thrombosis and Hemostasis Thieme Medical Publishers, Inc. Stuttgart, Germany 2021 Volume 47 950 961 10.1055/s-0041-1726298 34261150
4. Li X. Chen X. Gong S. Zhao J. Yao C. Zhu H. Xiao R. Qin Y. Li R. Sun N. Platelets promote CRC by activating the C5a/C5aR1 axis via PSGL-1/JNK/STAT1 signaling in tumor-associated macrophages Theranostics 2023 13 2040 2056 10.7150/thno.80555 37064877 PMC10091882
5. Mezouar S. Frère C. Darbousset R. Mege D. Crescence L. Dignat-George F. Panicot-Dubois L. Dubois C. Role of platelets in cancer and cancer-associated thrombosis: Experimental and clinical evidences Thromb. Res. 2016 139 65 76 10.1016/j.thromres.2016.01.006 26916298
6. Gomes F.G. Sandim V. Almeida V.H. Rondon A.M. Succar B.B. Hottz E.D. Leal A.C. Verçoza B.R.F. Rodrigues J.C.F. Bozza P.T. Breast-cancer extracellular vesicles induce platelet activation and aggregation by tissue factor-independent and -dependent mechanisms Thromb. Res. 2017 159 24 32 10.1016/j.thromres.2017.09.019 28950217
7. Stone R.L. Nick A.M. McNeish I.A. Balkwill F. Han H.D. Bottsford-Miller J. Rupaimoole R. Armaiz-Pena G.N. Pecot C.V. Coward J. Paraneoplastic thrombocytosis in ovarian cancer N. Engl. J. Med. 2012 366 610 618 10.1056/NEJMoa1110352 22335738 PMC3296780
8. Suzuki A. Takahashi T. Nakamura K. Tsuyuoka R. Okuno Y. Enomoto T. Fukumoto M. Imura H. Thrombocytosis in patients with tumors producing colony-stimulating factor Blood 1992 80 2052 2059 10.1182/blood.V80.8.2052.2052 1382717
9. Mege D. Aubert M. Lacroix R. Dignat-George F. Panicot-Dubois L. Dubois C. Involvement of Platelets in Cancers Seminars in Thrombosis and Hemostasis Thieme Medical Publishers, Inc. Stuttgart, Germany 2019 Volume 45 569 575 10.1055/s-0039-1693475 31382305
10. Laslo C.L. Bacalbasa N. Stanescu A.M.A. Carsote M. Bungau S. Rus M. Bratu O.G. Diaconu C.C. New oral anticoagulants—Possible extension to other indications (Review) Exp. Ther. Med. 2020 20 2401 2405 10.3892/etm.2020.8713 32765723 PMC7401725
11. Hong K.S. Non-Vitamin K Antagonist Oral Anticoagulants in Medical Conditions at High Risk of Thromboembolism beyond Atrial Fibrillation J. Stroke 2019 21 259 275 10.5853/jos.2019.01970 31590471 PMC6780021
12. Weitz J.I. Harenberg J. New developments in anticoagulants: Past, present and future Thromb. Haemost. 2017 117 1283 1288 10.1160/TH16-10-0807 28594426
13. Lee L.H. DOACs—Advances and limitations in real world Thromb. J. 2016 14 (Suppl. 1) 17 10.1186/s12959-016-0111-3 27766043 PMC5056491
14. Weronska A. Papuga-Szela E. Broniatowska E. Undas A. Nonvitamin K Antagonist Oral Anticoagulant in Patients With Venous Thromboembolism and Polycythemia Vera or Essential Thrombocythemia: A Cohort Study J. Cardiovasc. Pharmacol. 2021 78 e743 e748 10.1097/FJC.0000000000001112 34321399
15. Etxeandia-Ikobaltzeta I. Zhang Y. Brundisini F. Florez I.D. Wiercioch W. Nieuwlaat R. Begum H. Cuello C.A. Roldan Y. Chen R. Patient values and preferences regarding VTE disease: A systematic review to inform American Society of Hematology guidelines Blood Adv. 2020 4 953 968 Erratum in Blood Adv. 2020 , 4 , 1219 10.1182/bloodadvances.2019000462 32150612 PMC7065473
16. Noble S. Matzdorff A. Maraveyas A. Holm M.V. Pisa G. Assessing patients’ anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology Haematologica 2015 100 1486 1492 10.3324/haematol.2015.127126 26294737 PMC4825304
17. Overvad T.F. Larsen T.B. Søgaard M. Albertsen I.E. Ording A.G. Noble S. Højen A.A. Nielsen P.B. Cancer-associated venous thromboembolism and the non-vitamin K antagonist oral anticoagulants: A review of clinical outcomes and patient perspectives Expert Rev. Cardiovasc. Ther. 2020 18 791 800 10.1080/14779072.2020.1822167 32909840
18. Hutchinson A. Rees S. Young A. Maraveyas A. Date K. Johnson M.J. Oral anticoagulation is preferable to injected, but only if it is safe and effective: An interview study of patient and carer experience of oral and injected anticoagulant therapy for cancer-associated thrombosis in the select-d trial Palliat. Med. 2019 33 510 517 10.1177/0269216318815377 30488789 PMC6506899
19. Picker N. Lee A.Y. Cohen A.T. Maraveyas A. Beyer-Westendorf J. Mantovani L.G. Abdelgawwad K. Fatoba S. Thate-Waschke I.M. Bach M. Anticoagulation Treatment in Cancer-Associated Venous Thromboembolism: Assessment of Patient Preferences Using a Discrete Choice Experiment (COSIMO Study) Thromb. Haemost. 2021 121 206 215 10.1055/s-0040-1714739 32877956 PMC7850882
20. Lanéelle D. Le Brun C. Mauger C. Guillaumat J. Le Pabic E. Omarjee L. Mahé G. SFMV VTE Study Group Patient Characteristics and Preferences Regarding Anticoagulant Treatment in Venous Thromboembolic Disease Front. Cardiovasc. Med. 2021 8 675969 10.3389/fcvm.2021.675969 34235186 PMC8255622
21. Moyer G.C. Bannow B.S. Thornburg C. Rosovsky R. Wang T.F. Woller S. Thornhill D. Kreuziger L.B. Venous Thromboembolism: A Survey of Oral Anticoagulant Preferences in the Treatment of Challenging Patient Populations Clin. Appl. Thromb. Hemost. 2018 24 (Suppl. 9) 209S 216S 10.1177/1076029618804080 30278776 PMC6714851
22. Zhu J. Alexander G.C. Nazarian S. Segal J.B. Wu A.W. Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010–2017 Pharmacotherapy 2018 38 907 920 10.1002/phar.2158 29920705 PMC6448138
23. Shah S.B. Pahade A. Chawla R. Novel reversal agents and laboratory evaluation for direct-acting oral anticoagulants (DOAC): An update Indian J. Anaesth. 2019 63 169 181 10.4103/ija.IJA_734_18 30988530 PMC6423941
24. Di Cesare M. Jarvis J.D. Scarlatescu O. Leng X. Zaidel E.J. Burrone E. Eiselé J.L. Prabhakaran D. Silwa K. NOACs Added to WHO’s Essential Medicines List: Recommendations for Future Policy Actions Global Heart 2020 15 67 10.5334/gh.774 33150132 PMC7546116
25. Roehrig S. Straub A. Pohlmann J. Lampe T. Pernerstorfer J. Schlemmer K.H. Reinemer P. Perzborn E. Discovery of the novel antithrombotic agent 5-chloro-N-([(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1, 3-oxazolidin-5-yl]methyl)thiophene-2-carboxamide (BAY 59–7939): An oral, direct Factor Xa inhibitor J. Med. Chem. 2005 48 5900 5908 10.1021/jm050101d 16161994
26. Samama M.M. The mechanism of action of rivaroxaban-an oral, direct Factor Xa inhibitor-Compared with other anticoagulants Thromb. Res. 2011 127 497 504 10.1016/j.thromres.2010.09.008 20888031
27. Kubitza D. Becka M. Voith B. Zuehlsdorf M. Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor Clin. Pharmacol. Ther. 2005 78 412 421 10.1016/j.clpt.2005.06.011 16198660
28. European Medicines Agency: Xarelto European Medicines Agency 2023 Available online: https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto#authorisation-details-section (accessed on 27 February 2023)
29. Janssen Pharmaceuticals, Inc Xarelto (Rivaroxaban) Prescribing Information. Revised 02/2023 Available online: https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf (accessed on 17 February 2023)
30. Xarelto: EPAR-Product Information. Last Updated 23/02/2023 Available online: https://www.ema.europa.eu/en/documents/overview/xarelto-epar-medicine-overview_en.pdf (accessed on 17 April 2023)
31. Agrawal A. Kerndt C.C. Manna B. Apixaban StatPearls Publishing Tampa, FL, USA 2022 29939687
32. European Medicines Agency: Eliquis European Medicines Agency 2023 Available online: https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis (accessed on 27 February 2023)
33. Eliquis Prescribing Information. Revised 04/2021 Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202155s032lbl.pdf (accessed on 17 April 2023)
34. Eliquis: EPAR-Product Information. Last Updated 09/09/2022 Available online: https://www.ema.europa.eu/en/documents/product-information/eliquis-epar-product-information_en.pdf (accessed on 17 April 2023)
35. Padda I.S. Chowdhury Y.S. Chowdhury. Edoxaban StatPearls Publishing Tampa, FL, USA 2022 33351434
36. European Medicines Agency: Lixiana European Medicines Agency 2023 Available online: https://www.ema.europa.eu/en/medicines/human/EPAR/lixiana (accessed on 27 February 2023)
37. Savaysa Prescribing Information. Revised 01/2015 Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf (accessed on 17 April 2023)
38. Lixiana: EPAR-Product Information. Last Updated 23/04/2021 Available online: https://www.ema.europa.eu/en/documents/product-information/lixiana-epar-product-information_en.pdf (accessed on 17 April 2023)
39. Schwarb H. Tsakiris D.A. New Direct Oral Anticoagulants (DOAC) and Their Use Today Dent. J. 2016 4 5 10.3390/dj4010005 PMC5851208 29563447
40. Nagarakanti R. Ellis C.R. Dabigatran in clinical practice Clin. Ther. 2012 34 2051 2060 10.1016/j.clinthera.2012.09.008 23031622
41. European Medicines Agency: Pradaxa European Medicines Agency 2023 Available online: https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa (accessed on 28 February 2023)
42. Pradaxa Prescribing Information. Revised 06/2021 Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214358s000lbl.pdf (accessed on 17 April 2023)
43. Pradaxa: EPAR-Product Information. Last Updated 25/07/2022 Available online: https://www.ema.europa.eu/en/documents/product-information/pradaxa-epar-product-information_en.pdf (accessed on 17 April 2023)
44. Baglin T. Chapter 29—Drugs and haemostasis Clinical Pharmacology 11th ed. Bennett P.N. Brown M.J. Sharma P. Churchill Livingstone London, UK 2012 482 495 10.1016/B978-0-7020-4084-9.00068-9 9780702040849
45. Van den Heuvel J.M. Hövels A.M. Büller H.R. Mantel-Teeuwisse A.K. De Boer A. Maitland-Van Der Zee A.H. NOACs replace VKA as preferred oral anticoagulant among new patients: A drug utilization study in 560 pharmacies in The Netherlands Thromb. J. 2018 16 7 10.1186/s12959-017-0156-y 29692686 PMC5905161
46. Lee S.I. Sayers M. Lip G.Y.H. Lane D.A. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: Insights from a specialist atrial fibrillation clinic Int. J. Clin. 2015 69 1341 1348 10.1111/ijcp.12712 26234557
47. Mocek A. Weber V. Schmölders J. Witt H. Gothe H. Preferences for and use of oral anticoagulants for stroke prevention in atrial fibrillation under real-world conditions in Germany: A survey among physicians Prev. Med. Rep. 2022 28 101861 10.1016/j.pmedr.2022.101861 35757576 PMC9218143
48. Ravikumar R. Lim C.S. Davies A.H. The Role of New Oral Anticoagulants (NOACs) in Cancer Patients Adv. Exp. Med. Biol. 2017 906 137 148 10.1007/5584_2016_112 27620312
49. Vedovati M.C. Germini F. Agnelli G. Becattini C. Direct oral anticoagulants in patients with VTE and cancer: A systematic review and meta-analysis Chest 2015 147 475 483 10.1378/chest.14-0402 25211264
50. Larsen T.B. Nielsen P.B. Skjøth F. Rasmussen L.H. Lip G.Y. Non-vitamin K antagonist oral anticoagulants and the treatment of venous thromboembolism in cancer patients: A semi systematic review and meta-analysis of safety and efficacy outcomes PLoS ONE 2014 9 e114445 10.1371/journal.pone.0114445 25479007 PMC4257692
51. van der Hulle T. den Exter P.L. Kooiman J. van der Hoeven J.J. Huisman M.V. Klok F.A. Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism J. Thromb. Haemost. 2014 12 1116 1120 10.1111/jth.12605 24819040
52. Ebner M. Lankeit M. Antithrombotische Therapie bei Lungenembolie [Antithrombotic Treatment of Pulmonary Embolism] Dtsch. Med. Wochenschr. 2020 145 970 977 (In German) 10.1055/a-0955-3379 32668468
53. Yan Y.D. Zhang C. Shen L. Su Y.J. Liu X.Y. Wang L.W. Gu Z.C. Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants for Venous Thromboembolism Prophylaxis in Patients with Cancer: A Systematic Review and Trade-Off Analysis from 9 Randomized Controlled Trials Front Pharmacol. 2018 9 575 10.3389/fphar.2018.00575 29946255 PMC6005885
54. Malavasi V.L. Vitolo M. Proietti M. Diemberger I. Fauchier L. Marin F. Nabauer M. Potpara T.S. Dan G.A. Kalarus Z. Impact of malignancy on outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EURObservational research programme in atrial fibrillation general long-term registry Eur. J. Clin. Investig. 2022 52 e13773 10.1111/eci.13773 35305020
55. Wumaier K. Li W. Cui J. New Oral Anticoagulants Open New Horizons for Cancer Patients with Venous Thromboembolism Drug Des. Devel. Ther. 2022 16 2497 2507 10.2147/DDDT.S373726 PMC9357558 35959418
56. Mohamed M.F.H. ElShafei M.N. Ahmed M.B. Abdalla L.O. Ahmed I. Elzouki A.N. Danjuma M.I. The Net Clinical Benefit of Rivaroxaban Compared to Low-Molecular-Weight Heparin in the Treatment of Cancer-Associated Thrombosis: Systematic Review and Meta-Analysis Clin. Appl. Thromb. Hemost. 2021 27 1076029620940046 10.1177/1076029620940046 33651658 PMC7930650
57. Prandoni P. Lensing A.W. Piccioli A. Bernardi E. Simioni P. Girolami B. Marchiori A. Sabbion P. Prins M.H. Noventa F. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis Blood 2002 100 3484 3488 10.1182/blood-2002-01-0108 12393647
58. Zhang J. Xu J. Zhang W. Jiang M. Liu J. Xu L. Liu G. Zhao Z. Quality Appraisal of Guidelines on Cancer-Associated Thrombosis Using AGREE II Instrument and Analysis of Current Status of New Oral Anticoagulants Clin. Appl. Thromb. Hemost. 2019 25 1076029619846562 10.1177/1076029619846562 31025571 PMC6714899
59. Mekaj Y.H. Mekaj A.Y. Duci S.B. Miftari E.I. New oral anticoagulants: Their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events Ther. Clin. Risk Manag. 2015 11 967 977 10.2147/TCRM.S84210 26150723 PMC4485791
60. Kim H. Lee Y.S. Kim T.H. Cha M.J. Lee J.M. Park J. Park J.K. Kang K.W. Shim J. Uhm J.S. A prospective survey of the persistence of warfarin or NOAC in nonvalvular atrial fibrillation: A comparison study of Drugs for symptom control and complication prevention of Atrial Fibrillation (CODE-AF) Korean J. Intern. Med. 2020 35 99 108 10.3904/kjim.2017.415 31014064 PMC6960047
61. Iorga R.A. Bratu O.G. Marcu R.D. Constantin T. Mischianu D.L.D. Socea B. Gaman M.A. Diaconu C.C. Venous thromboembolism in cancer patients: Still looking for answers Exp. Ther. Med. 2019 18 5026 5032 10.3892/etm.2019.8019 31819767 PMC6895781
62. Dong S. Zhang Y. Li Y. Li Y. Miao Y. Zhao R. Zhai S. Direct Oral Anticoagulant for the Treatment of VTE in Cancer Patients: A Systematic Review and Meta-analysis Ann. Pharmacother. 2021 55 430 439 10.1177/1060028020960037 32938202
63. Raskob G.E. van Es N. Segers A. Angchaisuksiri P. Oh D. Boda Z. Lyons R.M. Meijer K. Gudz I. Weitz J.I. Edoxaban for venous thromboembolism in patients with cancer: Results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial Lancet Haematol. 2016 3 e379 e387 10.1016/S2352-3026(16)30057-6 27476789
64. Karakatsanis S.J. Roumpi A. Syrigos K.N. The use of novel oral anticoagulants in cancer patients with venous thromboembolism Semin. Oncol. 2016 43 655 665 10.1053/j.seminoncol.2016.11.009 28061983
65. Wang C.X. Wu D. Yang P.P. Wu Q.H. Efficacy and safety of non-vitamin K antagonist versus vitamin K antagonist oral anticoagulants in the prevention and treatment of thrombotic disease in active cancer patients: A systematic review and meta-analysis of randomized controlled trials Zhonghua Xin Xue Guan Bing Za Zhi 2020 48 689 696 (In Chinese) 10.3760/cma.j.cn112148-20200630-00529 32847326
66. Verso M. Agnelli G. Prandoni P. Pros and cons of new oral anticoagulants in the treatment of venous thromboembolism in patients with cancer Intern. Emerg. Med. 2015 10 651 656 10.1007/s11739-015-1233-5 25840679
67. Haas S. Farjat A.E. Pieper K. Ageno W. Angchaisuksiri P. Bounameaux H. Goldhaber S.Z. Goto S. Mantovani L. Prandoni P. On-treatment Comparative Effectiveness of Vitamin K Antagonists and Direct Oral Anticoagulants in GARFIELD-VTE, and Focus on Cancer and Renal Disease TH Open 2022 6 e354 e364 10.1055/s-0042-1757744 36452204 PMC9633227
68. Barbarawi M. Barbarawi O. Corcoran J. Obeidat K. Al-Abdouh A. Mhanna M. Al Kasasbeh M. Pickett C.C. Efficacy and Safety of the Non-Vitamin K Antagonist Oral Anticoagulant Among Patients with Nonvalvular Atrial Fibrillation and Cancer: A Systematic Review and Network Meta-analysis Curr. Probl. Cardiol. 2022 47 101346 10.1016/j.cpcardiol.2022.101346 35932849
69. Chan Y.H. Chao T.F. Lee H.F. Chen S.W. Li P.R. Liu J.R. Wu L.S. Chang S.H. Yeh Y.H. Kuo C.T. Clinical Outcomes in Atrial Fibrillation Patients with a History of Cancer Treated with Non-Vitamin K Antagonist Oral Anticoagulants: A Nationwide Cohort Study Stroke 2021 52 3132 3141 10.1161/STROKEAHA.120.033470 34233467
70. Clemens A. Strack A. Noack H. Konstantinides S. Brueckmann M. Lip G.Y. Anticoagulant-related gastrointestinal bleeding--could this facilitate early detection of benign or malignant gastrointestinal lesions? Ann. Med. 2014 46 672 678 10.3109/07853890.2014.952327 25174259
71. Papanastasiou A. Morsi-Yeroyannis A. Karagiannidis E. Kartas A. Doundoulakis I. Karvounis H. Giannakoulas G. Association of anticoagulant-related bleeding events with cancer detection in atrial fibrillation: A systematic review and meta-analysis Hell. J. Cardiol. 2021 62 359 365 10.1016/j.hjc.2020.11.007 33242617
72. Chang T.Y. Chan Y.H. Chiang C.E. Lin Y.J. Chang S.L. Lo L.W. Hu Y.F. Tuan T.C. Liao J.N. Chung F.P. Risks and outcomes of gastrointestinal malignancies in anticoagulated atrial fibrillation patients experiencing gastrointestinal bleeding: A nationwide cohort study Heart Rhythm. 2020 17 1745 1751 10.1016/j.hrthm.2020.05.026 32470625
73. Antunes L.F. New Oral Anticoagulants (NOACs) are The Gold Standard Invenous Thromboembolism Rev. Port. Cir. Cardiotorac. Vasc. 2020 27 33 37 32239823
74. Choi Y.J. Choi Y.W. Chae J.W. Yun H.Y. Shin S. Clinical Benefits of Oral Anticoagulant Use in Cancer Patients at Increased Risk for Venous Thromboembolism per Khorana Index Risk Manag. Healthc. Policy 2021 14 1855 1867 10.2147/RMHP.S306760 33994816 PMC8114826
75. Chen Y. Mao M. Chang J. Yan J. Yang T. Liu Y. Luo M. Hu Y. Yang Q. Zhou L. Safety and efficacy of new oral anticoagulants compared to those of warfarin in AF patients with cancer: A meta-analysis of randomized clinical trials and observational studies Eur. J. Clin. Pharmacol. 2021 77 849 857 10.1007/s00228-021-03132-x 33791828
76. Wu V.C. Wang C.L. Huang Y.T. Lan W.C. Wu M. Kuo C.F. Chen S.W. Chu P.H. Wen M.S. Kuo C.C. Novel Oral Anticoagulant versus Warfarin in Cancer Patients with Atrial Fibrillation: An 8-Year Population-Based Cohort Study J. Cancer 2020 11 92 99 10.7150/jca.36468 31892976 PMC6930400
77. Kim K. Lee Y.J. Kim T.H. Uhm J.S. Pak H.N. Lee M.H. Joung B. Effect of Non-vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients with Newly Diagnosed Cancer Korean Circ. J. 2018 48 406 417 10.4070/kcj.2017.0328 29671285 PMC5940645
78. Atterman A. Asplund K. Friberg L. Engdahl J. Use of oral anticoagulants after ischemic stroke in patients with atrial fibrillation and cancer J. Intern. Med. 2020 288 457 468 10.1111/joim.13092 32386073
79. Solari F. Varacallo M. Low Molecular Weight Heparin (LMWH) StatPearls Publishing Treasure Island, FL, USA 2018 30247832
80. Mulloy B. Hogwood J. Gray E. Lever R. Page C.P. Pharmacology of Heparin and Related Drugs Pharmacol. Rev. 2016 68 76 141 10.1124/pr.115.011247 26672027
81. Howard L.S. Non-vitamin K antagonist oral anticoagulants for pulmonary embolism: Who, where and for how long? Expert Rev. Respir. Med. 2018 12 387 402 10.1080/17476348.2018.1452614 29542359
82. Short N.J. Connors J.M. New oral anticoagulants and the cancer patient Oncologist 2014 19 82 93 10.1634/theoncologist.2013-0239 24319019 PMC3903061
83. Enea I. Roncon L. Gulizia M.M. Azzarito M. Becattini C. Bongarzoni A. Casazza F. Cuccia C. D’Agostino C. Rugolotto M. ANMCO Position Paper: The use of non-vitamin K dependent new oral anticoagulant(s) in pulmonary embolism therapy and prevention Eur. Heart J. Suppl. 2017 19 (Suppl. D) D293 D308 10.1093/eurheartj/sux026 28751847 PMC5526474
84. Al-Samkari H. Connors J.M. The Role of Direct Oral Anticoagulants in Treatment of Cancer-Associated Thrombosis Cancers 2018 10 271 10.3390/cancers10080271 30111746 PMC6115910
85. Stepien K. Nowak K. Zalewski J. Pac A. Undas A. Extended treatment with non-vitamin K antagonist oral anticoagulants versus low-molecular-weight heparins in cancer patients following venous thromboembolism. A pilot study Vascul. Pharmacal. 2019 120 106567 10.1016/j.vph.2019.106567 31158568
86. Tirandi A. Preda A. Carbone F. Montecucco F. Liberale L. Pulmonary embolism in patients with cancer: An updated and operative guide for diagnosis and management Int. J. Cardiol. 2022 358 95 102 10.1016/j.ijcard.2022.04.068 35489655
87. Asnani A. Manning A. Mansour M. Ruskin J. Hochberg E.P. Ptaszek L.M. Management of atrial fibrillation in patients taking targeted cancer therapies Cardiooncology 2017 3 2 10.1186/s40959-017-0021-y 32153998 PMC7048041
88. Jin C. Cui C. Seplowe M. Lee K.I. Vegunta R. Li B. Frishman W.H. Iwai S. Anticoagulation for Atrial Fibrillation: A Review of Current Literature and Views Cardiol. Rev. 2022 10.1097/CRD.0000000000000489 36730534
89. Stevens S.M. Woller S.C. Kreuziger L.B. Bounameaux H. Doerschug K. Geersing G.J. Huisman M.V. Kearon C. King C.S. Knighton A.J. Antithrombotic therapy for VTE disease: Second update of the CHEST guideline and expert panel report Chest 2021 160 e545 e608 10.1016/j.chest.2021.07.055 34352278
90. Gressel G.M. Marcus J.Z. Mullen M.M. Sinno A.K. Direct oral anticoagulant use in gynecologic oncology: A Society of Gynecologic Oncology Clinical Practice Statement Gynecol. Oncol. 2021 160 312 321 10.1016/j.ygyno.2020.11.020 33257014
91. Ren J.W. Zheng X. Han X.H. Generic Methods for Simultaneous Analysis of Four Direct Oral Anticoagulants in Human Plasma and Urine by Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry Molecules 2023 28 2254 10.3390/molecules28052254 36903499 PMC10004761
92. Lenihan D.J. Fradley M.G. Dent S. Brezden-Masley C. Carver J. Filho R.K. Neilan T.G. Blaes A. Melloni C. Herrmann J. Proceedings from the Global Cardio-Oncology Summit: The Top 10 Priorities to Actualize for CardioOncology JACC CardioOncol. 2019 1 256 272 10.1016/j.jaccao.2019.11.007 34396188 PMC8352295
93. Khorana A.A. Kuderer N.M. Culakova E. Lyman G.H. Francis C.W. Development and validation of a predictive model for chemotherapy-associated thrombosis Blood 2008 111 4902 4907 10.1182/blood-2007-10-116327 18216292 PMC2384124
94. Key N.S. Khorana A.A. Kuderer N.M. Bohlke K. Lee A.Y.Y. Arcelus J.I. Wong S.L. Balaban E.P. Flowers C.R. Francis C.W. Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer: ASCO Clinical Practice Guideline Update J. Clin. Oncol. 2020 38 496 520 10.1200/JCO.19.01461 31381464
95. Falanga A. Ay C. Di Nisio M. Gerotziafas G. Langer F. Lecumberri R. Mandala M. Maraveyas A. Pabinger I. Jara-Palomares L. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline Ann. Oncol. 2023 34 452 467 10.1016/j.annonc.2022.12.014 36638869
96. Streiff M.B. Holmstrom B. Angelini D. Ashrani A. Elshoury A. Fanikos J. Fertrin K.Y. Fogerty A.E. Gao S. Goldhaber S.Z. Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology J. Natl. Compr. Cancer Netw. 2021 19 1181 1201 10.6004/jnccn.2021.0047 34666313
97. Lyman G.H. Carrier M. Ay C. Di Nisio M. Hicks L.K. Khorana A.A. Leavitt A.D. Lee A.Y.Y. Macbeth F. Morgan R.L. American Society of Hematology 2021 guidelines for management of venous thromboembolism: Prevention and treatment in patients with cancer Blood Adv. 2021 5 927 974 10.1182/bloodadvances.2020003442 33570602 PMC7903232
98. Li M. Li J. Wang X. Hui X. Wang Q. Xie S. Yan P. Tian J. Li J. Xie P. Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism Cochrane Database Syst. Rev. 2023 4 CD010957 10.1002/14651858.CD010957.pub3 37057837 PMC10103165
99. Barca-Hernando M. Lopez-Ruz S. Marin-Romero S. Garcia-Garcia V. Elias-Hernandez T. Otero-Candelera R. Carrier M. Jara-Palomares L. Risk of recurrent cancer-associated thrombosis after discontinuation of anticoagulant therapy Res. Pract. Thromb. Haemost. 2023 7 100115 10.1016/j.rpth.2023.100115 37063761 PMC10099299
100. Debourdeau P. Bertoletti L. Font C. López-Núñez J.J. Gómez-Cuervo C. Mahe I. Otero-Candelera R. Adarraga M.D. López-Miguel P. Monreal M. Three-Month Outcomes in Cancer Patients with Superficial or Deep Vein Thrombosis in the Lower Limbs: Results from the RIETE Registry Cancers 2023 15 2034 10.3390/cancers15072034 37046695 PMC10093050
101. Robinson R. Spectre G. Lishner M. Sharabi O. Robinson E. Hamburger Avnery O. Gafter-Gvili A. Raanani P. Leader A. Direct oral anticoagulants in patients with venous thromboembolism and hematological malignancies J. Thromb. Thrombolysis 2023 55 729 736 10.1007/s11239-023-02791-0 36943661
102. Wiklund P. Medson K. Elf J. Unreported incidental pulmonary embolism in patients with cancer: Radiologic natural history and risk of recurrent venous thromboembolism and death Thromb. Res. 2023 224 65 72 10.1016/j.thromres.2023.02.010 36867992
103. Vedovati M.C. Giustozzi M. Munoz A. Bertoletti L. Cohen A.T. Klok F.A. Connors J.M. Bauersachs R. Brenner B. Campanini M. Risk factors for recurrence and major bleeding in patients with cancer-associated venous thromboembolism Eur. J. Intern. Med. 2023 ahead of print 10.1016/j.ejim.2023.02.003 36774305
104. Li A. Garcia D.A. Lyman G.H. Carrier M. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis Thromb. Res. 2019 173 158 163 10.1016/j.thromres.2018.02.144 29506866 PMC6119655
105. Lv S. Liu Y. Wei G. Shi X. Chen S. Zhang X. The anticoagulants rivaroxaban and low molecular weight heparin prevent PICC-related upper extremity venous thrombosis in cancer patients Medicine 2019 98 e17894 10.1097/MD.0000000000017894 31764785 PMC6882624
106. Longo de Oliveira A.L.M. de Oliveira Pereira R.F. Agati L.B. Ribeiro C.M. Kawamura Suguiura G.Y. Cioni C.H. Bermudez M. Pirani M.B. Caffaro R.A. Castelli V. Jr. Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After major Gynecological Cancer Surgery: The VALERIA Trial: Venous thromboembolism prophylAxis after gynecoLogical pElvic cancer surgery with RIvaroxaban versus enoxAparin (VALERIA trial) Clin. Appl. Thromb. Hemost. 2022 28 10760296221132556 10.1177/10760296221132556 36474344 PMC9732794
107. Chen D.Y. Tseng C.N. Hsieh M.J. Lan W.C. Chuang C.K. Pang S.T. Chen S.W. Chen T.H. Chang S.H. Hsieh I.C. Comparison between Non-vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism JAMA Netw. Open 2021 4 e2036304 10.1001/jamanetworkopen.2020.36304 33533929 PMC7859846
108. Song A.B. Rosovsky R.P. Connors J.M. Al-Samkari H. Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients Vasc. Health Risk Manag. 2019 15 175 186 10.2147/VHRM.S132556 31417269 PMC6593743
109. Camilli M. Lombardi M. Vescovo G.M. Del Buono M.G. Galli M. Aspromonte N. Zoccai G.B. Niccoli G. Montone R.A. Crea F. Efficacy and safety of novel oral anticoagulants versus low molecular weight heparin in cancer patients with venous thromboembolism: A systematic review and meta-analysis Crit. Rev. Oncol. Hematol. 2020 154 103074 10.1016/j.critrevonc.2020.103074 32911455
110. Raskob G.E. van Es N. Verhamme P. Carrier M. Di Nisio M. Garcia D. Grosso M.A. Kakkar A.K. Kovacs M.J. Mercuri M.F. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism N. Engl. J. Med. 2018 378 615 624 10.1056/NEJMoa1711948 29231094
111. Wang K.L. Kao Y.T. Chang W.T. Chang H.Y. Huang W.C. Hsu P.C. Hsu C.H. Huang C.L. Hsieh L.C. Wang C.Y. Management of Venous Thromboembolisms: Part, I.I. The Consensus for Pulmonary Embolism and Updates Acta Cardiol. Sin. 2020 36 562 582 10.6515/ACS.202011_36(6).20200917A 33235412 PMC7677645
112. Hussain M.R. Ali F.S. Verghese D. Myint P.T. Ahmed M. Gong Z. Gerais Y. Siddiqui M. Lin J.J. Troy K. Factor Xa inhibitors versus low molecular weight heparin for the treatment of cancer associated venous thromboembolism; A meta-analysis of randomized controlled trials and non-randomized studies Crit. Rev. Oncol. Hematol. 2022 169 103526 10.1016/j.critrevonc.2021.103526 34838704
113. Frere C. Farge D. Schrag D. Prata P.H. Connors J.M. Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials J. Hematol. Oncol. 2022 15 69 10.1186/s13045-022-01289-1 35598026 PMC9124390
114. Nam K.W. Kim C.K. Kim T.J. An S.J. Oh K. Ko S.B. Yoon B.W. Treatment of Cryptogenic Stroke with Active Cancer with a New Oral Anticoagulant J. Stroke Cerebrovasc. Dis. 2017 26 2976 2980 10.1016/j.jstrokecerebrovasdis.2017.07.029 28843806
115. Jiménez-Fonseca P. Gallardo E. Arranz Arija F. Blanco J.M. Callejo A. Lavin D.C. Costa Rivas M. Mosquera J. Rodrigo A. Sánchez Morillas R. Consensus on prevention and treatment of cancer-associated thrombosis (CAT) in controversial clinical situations with low levels of evidence Eur. J. Intern. Med. 2022 100 33 45 10.1016/j.ejim.2022.02.020 35227541
116. Delluc A. Wang T.F. Yap E.S. Ay C. Schaefer J. Carrier M. Noble S. Anticoagulation of cancer patients with non-valvular atrial fibrillation receiving chemotherapy: Guidance from the SSC of the ISTH J. Thromb. Haemost. 2019 17 1247 1252 10.1111/jth.14478 31207027
117. Undas A. Drabik L. Non-vitamin K antagonist oral anticoagulants (NOACs) in cancer patients with atrial fibrillation Anatol. J. Cardiol. 2020 23 10 18 10.14744/AnatolJCardiol.2019.30766 31911561 PMC7141434
118. Ferri N. Colombo E. Tenconi M. Baldessin L. Corsini A. Drug-Drug Interactions of Direct Oral Anticoagulants (DOACs): From Pharmacological to Clinical Practice Pharmaceutics 2022 14 1120 10.3390/pharmaceutics14061120 35745692 PMC9229376
119. Otten L.S. Piet B. van den Heuvel M.M. Marzolini C. van Geel R.M.J.M. Gulikers J.L. Burger D.M. Leentjens J. Ter Heine R. Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancer Eur. Respir. Rev. 2022 31 220004 10.1183/16000617.0004-2022 35705208 PMC9489148
120. Hellfritzsch M. Henriksen J.N. Holt M.I. Grove E.L. Drug-Drug Interactions in the Treatment of Cancer-Associated Venous Thromboembolism with Direct Oral Anticoagulants Seminars in Thrombosis and Hemostasis Thieme Medical Publishers, Inc. Leipzig, Germany 2023 10.1055/s-0043-1762596 36731488
121. Rousseau A. Van Dreden P. Mbemba E. Elalamy I. Larsen A. Gerotziafas G.T. Cancer cells BXPC3 and MCF7 differentially reverse the inhibition of thrombin generation by apixaban, fondaparinux and enoxaparin Thromb. Res. 2015 136 1273 1279 10.1016/j.thromres.2015.08.009 26489727
122. Muñoz Martín A.J. Gallardo Díaz E. García Escobar I. Macías Montero R. Martínez-Marín V. Pachón Olmos V. Pérez Segura P. Quintanar Verdúguez T. Salgado Fernández M. SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019) Clin. Transl. Oncol. 2020 22 171 186 10.1007/s12094-019-02263-z 31981080
123. Tran H.A. Gibbs H. Merriman E. Curnow J.L. Young L. Bennett A. Tan C.W. Chunilal S.D. Ward C.M. Baker R. New guidelines from the Thrombosis and Haemostasis Society of Australia and New Zealand for the diagnosis and management of venous thromboembolism Med. J. Aust. 2019 210 227 235 Erratum in Med. J. Aust. 2019 , 211 , 94; Erratum in Med. J. Aust. 2020 , 212 , 108 10.5694/mja2.50004 30739331
124. Nayak A.L. Zahrai A. Mallick R. Wang T.F. Delluc A. Castellucci L.A. Carrier M. Wells P.S. Efficacy of primary prevention of venous thromboembolism among subgroups of cancer patients undergoing chemotherapy: A post- hoc analysis of the AVERT trial Thromb. Res. 2021 208 79 82 10.1016/j.thromres.2021.10.018 34742140
125. Ladha D. Mallick R. Wang T.F. Caiano L. Wells P.S. Carrier M. Efficacy and safety of apixaban for primary prevention in gastrointestinal cancers: A post-hoc analysis of the AVERT trial Thromb. Res. 2021 202 151 154 10.1016/j.thromres.2021.03.013 33857789
126. Brandt W. Brown C. Wang T.F. Tagalakis V. Shivakumar S. Ciuffini L.A. Mallick R. Wells P.S. Carrier M. Efficacy and safety of apixaban for primary prevention of thromboembolism in patients with cancer and a central venous catheter: A subgroup analysis of the AVERT Trial Thromb. Res. 2022 216 8 10 10.1016/j.thromres.2022.05.014 35660801
127. Wang T.F. Mallick R. Carrier M. Wells P.S. Safety and efficacy of apixaban thromboprophylaxis in ambulatory cancer patients according to renal function: A subgroup analysis of the AVERT trial Thromb. Res. 2022 211 85 87 10.1016/j.thromres.2022.01.022 35124234
128. Knoll W. Mallick R. Wells P.S. Carrier M. Safety and efficacy of apixaban thromboprophylaxis in cancer patients with metastatic disease: A post-hoc analysis of the AVERT trial Thromb. Res. 2021 197 13 15 10.1016/j.thromres.2020.10.026 33160115
129. Zhang J. Atalla M. Mallick R. Wells P.S. Carrier M. Thromboprophylaxis for patients with newly diagnosed vs. recurrent cancers: A post-hoc analysis of the avert trial J. Thromb. Thrombolysis 2021 51 720 724 10.1007/s11239-020-02317-y 33079379
130. Mones J.V. Streiff M.B. Khorana A.A. Bendheim G.A. Damaraju C.V. Wildgoose P. Burton P. Riess H. Soff G.A. Rivaroxaban thromboprophylaxis for gastric/gastroesophageal junction tumors versus other tumors: A post hoc analysis of the randomized CASSINI trial Res. Pract. Thromb. Haemost. 2021 5 e12549 10.1002/rth2.12549 34308096 PMC8292144
131. Khorana A.A. McNamara M.G. Kakkar A.K. Streiff M.B. Riess H. Vijapurkar U. Kaul S. Wildgoose P. Soff G.A. CASSINI Investigators Assessing Full Benefit of Rivaroxaban Prophylaxis in High-Risk Ambulatory Patients with Cancer: Thromboembolic Events in the Randomized CASSINI Trial TH Open 2020 4 e107 e112 10.1055/s-0040-1712143 32462111 PMC7245534
132. Vadhan-Raj S. McNamara M.G. Venerito M. Riess H. O’Reilly E.M. Overman M.J. Zhou X. Vijapurkar U. Kaul S. Wildgoose P. Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre-specified subgroup analysis of the randomized CASSINI study Cancer Med. 2020 9 6196 6204 10.1002/cam4.3269 32663379 PMC7476843
133. Khorana A.A. Soff G.A. Kakkar A.K. Vadhan-Raj S. Riess H. Wun T. Streiff M.B. Garcia D.A. Liebman H.A. Belani C.P. Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer N. Engl. J. Med. 2019 380 720 728 10.1056/NEJMoa1814630 30786186
134. National Library of Medicine (U.S.) Interaction between Direct Oral Anticoagulants and Drug-Metabolizing Enzyme Inducers. Identifier: NCT05750680 2021 Available online: https://clinicaltrials.gov/ct2/show/NCT05750680 (accessed on 15 March 2023)
135. National Library of Medicine (U.S.) Clinical Application Model of Direct Oral Anticoagulants (MACACOD). Comprehensive Management of ACOD from a Specialized Center in Antithrombotic Therapy and Its Area of Influence Identifier: NCT04042155 2019 Available online: https://clinicaltrials.gov/ct2/show/NCT04042155 (accessed on 15 March 2023)
136. National Library of Medicine (U.S.) Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial). Identifier: NCT02744092 2016 Available online: https://clinicaltrials.gov/ct2/show/NCT02744092 (accessed on 15 March 2023)
137. National Library of Medicine (U.S.) VICTORIE (VTE In Cancer—Treatment, Outcomes and Resource Use in Europe). Identifier: NCT04618913 Available online: https://clinicaltrials.gov/ct2/show/NCT04618913 (accessed on 15 March 2023)
138. Castle J. Blower E. Bundred N.J. Harvey J.R. Thachil J. Marshall A. Cox K. Cicconi S. Holcombe C. Palmieri C. Rivaroxaban compared to no treatment in ER-negative stage I-III early breast cancer patients (the TIP Trial): Study protocol for a phase II preoperative window-of-opportunity study design randomised controlled trial Trials 2020 21 749 10.1186/s13063-020-04675-7 32854772 PMC7534806
139. National Library of Medicine (U.S.) Observational Studies in Cancer Associated Thrombosis for Rivaroxaban in Sweden (OSCAR-SE). Identifier: NCT05150938 2022 Available online: https://clinicaltrials.gov/ct2/show/study/NCT05150938 (accessed on 15 March 2023)
140. National Library of Medicine (U.S.) Primary Thromboprophylaxis in Patients with Malignancy and Central Venous Catheters: A Randomized Controlled Trial. Identifier: NCT05029063 2022 Available online: https://clinicaltrials.gov/ct2/show/NCT05029063 (accessed on 15 March 2023)
141. National Library of Medicine (U.S.) Bleeding Risk Guided VTE Prophylaxis Strategy for Hospitalized Patients with Lung Cancer: Rationale and Design for a Multicenter, Adjudicator-Blinded, Parallel, Randomized Clinical Trial in China. Identifier: NCT04158973 2021 Available online: https://clinicaltrials.gov/ct2/show/NCT04158973 (accessed on 15 March 2023)
142. National Library of Medicine (U.S.) Venous Thromboembolism Prevention in Outpatients with Glioma. Identifier: NCT05683808 2023 Available online: https://clinicaltrials.gov/ct2/show/NCT05683808 (accessed on 15 March 2023)
143. National Library of Medicine (U.S.) Cost Comparison between Apixaban and Low Molecular Weight Heparin (LMWH) among Venous Thromboembolism (VTE) Cancer Patients. Identifier: NCT05643885 2022 Available online: https://clinicaltrials.gov/ct2/show/NCT05643885 (accessed on 15 March 2023)
144. National Library of Medicine (U.S.) A Multicenter, Randomized, Open-Label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab Relative to Apixaban on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients with Cancer Associated VTE. Identifier: NCT05171049 2022 Available online: https://clinicaltrials.gov/ct2/show/NCT05171049 (accessed on 15 March 2023)
145. Planquette B. Bertoletti L. Charles-Nelson A. Laporte S. Grange C. Mahé I. Pernod G. Elias A. Couturaud F. Falvo N. Rivaroxaban vs. Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial Chest 2022 161 781 790 10.1016/j.chest.2021.09.037 34627853
146. Agnelli G. Becattini C. Meyer G. Muñoz A. Huisman M.V. Connors J.M. Cohen A. Bauersachs R. Brenner B. Torbicki A. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer N. Engl. J. Med. 2020 382 1599 1607 10.1056/NEJMoa1915103 32223112
147. Canonico M.E. Santoro C. Avvedimento M. Giugliano G. Mandoli G.E. Prastaro M. Franzone A. Piccolo R. Ilardi F. Cameli M. Venous Thromboembolism and Cancer: A Comprehensive Review from Pathophysiology to Novel Treatment Biomolecules 2022 12 259 10.3390/biom12020259 35204760 PMC8961522